简式权益变动报告书 黑龙江珍宝岛药业股份有限公司 上市公司名称:黑龙江珍宝岛药业股份有限公司 股票上市地点:上海证券交易所 股票简称：珍宝岛 股票代码：603567 信息披露义务人：黑龙江创达集团有限公司 住所/通讯地址：虎林市解放西街北检察院东侧宝润香林里1号楼1号门市 股份变动性质：股份减少 签署日期：2026年2月9日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动 报告书》等相关法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证 券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报告书 已全面披露信息披露义务人在黑龙江珍宝岛药业股份有限公司中拥有权益的股份变 动情况。 | 公司、上市公司、珍宝岛 | 指 | 黑龙江珍宝岛药业股份有限公司 | | --- | --- | --- | | 信息披露义务人、创达集团 | 指 | 黑龙江创达集团有限公司 | | "23创01 ...

Core Viewpoint - The announcement indicates a reduction in shareholding by Heilongjiang Chuangda Group Co., Ltd. due to the exchange of corporate bonds, resulting in a decrease in ownership percentage from 55.86% to 54.94% [1] Group 1 - Heilongjiang Chuangda Group Co., Ltd. has reduced its shareholding by 8.7097 million shares during the period from February 5 to February 9, 2026 [1] - After the equity change, Chuangda Group holds a total of 516,973,085 shares, representing 54.94% of the company's total equity [1]

Core Viewpoint - The announcement details the completion of additional share pledges by the controlling shareholder of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., aimed at securing a bond issuance, with significant implications for the company's financial stability and shareholder structure [1][2]. Group 1: Share Pledge Details - As of February 5, 2026, the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 523,231,148 shares, representing 55.60% of the total share capital, with 421,115,848 shares pledged, accounting for 80.48% of its holdings [2][4]. - The controlling shareholder has pledged an additional 1,170,000 shares to secure the 23 Chuang 02EB bond, with the pledge completed on February 6, 2026 [3][4]. - The total number of pledged shares has decreased due to a bond conversion, with the previous pledge count adjusted accordingly [4]. Group 2: Financial Health and Risk Assessment - The controlling shareholder has no significant litigation or arbitration issues related to debt, and its operational and performance status is normal, with debt repayment sources identified [9][10]. - The controlling shareholder's total outstanding exchangeable bonds amount to 427.25 million yuan, with no immediate repayment risks identified [9]. - The company assesses that the current pledge situation does not pose a risk of forced liquidation or transfer, and the controlling shareholder is expected to take proactive measures if necessary [10].

● 截至 2026 年 2 月 5 日，黑龙江珍宝岛药业股份有限公司（以下简称"公 司"）控股股东黑龙江创达集团有限公司（以下简称"创达集团"）持有公司股份 523,231,148 股，占公司总股本的 55.60%，其累计质押公司股份数量 421,115,848 股，占所持公司股份数量的 80.48%，无一致行动人。 一、上市公司股份补充质押 近日，公司收到创达集团通知，根据黑龙江创达集团有限公司-2023 年面向 专业投资者非公开发行可交换公司债券（第二期）（以下简称"23 创 02EB"）债 券发行相关约定并结合其目前的担保情况，创达集团拟将其持有的 1,170,000 股公司股份（无限售流通股）补充质押给 23 创 02EB 的受托管理人中德证券有限 责任公司（以下简称"中德证券"），并将该部分股份划转至创达集团与中德证券 在中国证券登记结算有限责任公司上海分公司开立的 23 创 02EB 质押专户（详见 公司于 2026 年 2 月 4 日在上海证券交易所网站披露的相关公告）。 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 补充质押股份办理完成的公告 本公司董事会及全体董事保证本 ...

Core Insights - The core viewpoint of the news is that the Bozhou Traditional Chinese Medicine Commodity Trading Center has officially released its 2026 operational plan, focusing on brand leadership and a "1+5" development strategy to ensure sustained growth in performance for 2026 [1] Group 1: Brand Strategy - The trading center will elevate brand building to a strategic core, aiming to enhance the recognition and influence of the "BoJiao" brand in the traditional Chinese medicine industry through integrated marketing and multi-dimensional communication [1] - The center plans to develop the "Shen Nong Zhou Ben Cao Zhen Xuan" IP, enhancing content e-commerce and live streaming operations to create a closed loop of "content-fans-transaction" to empower physical merchants and explore new growth channels [1] Group 2: Business Segments - The trading center will upgrade five main business segments to form a solid support for development, including: - **Herb Procurement Business**: Focused on reducing procurement costs and stabilizing the supply chain through strategic partnerships with core clients like Jiuzhou Fangyuan, aiming to establish a quality-controlled and traceable supply system [2] - **Bulk Trading Business**: Transitioning from "transaction matching" to "ecological service provider," focusing on building services, increasing platform traffic, and creating a professional B2B e-commerce platform for traditional Chinese medicine [2] - **Fresh Processing Business**: Collaborating closely with strategic partner Jiuzhou Fangyuan to expand the fresh processing industry chain, integrating upstream processing capacity through acquisitions and controlling core raw material resources [2] Group 3: Market Operations - The offline market operations will aim to increase profitability and stabilize merchant recruitment, with specific goals including ensuring rental income, raising the occupancy rate to over 95%, and optimizing market image through standardized practices [3] - The warehousing business will shift from passive rent collection to active management and profit center development, expanding value-added services such as third-party regulatory warehousing and supply chain finance [3] Group 4: Strategic Framework - The introduction of the "1+5" strategic system marks a new phase for the Bozhou Traditional Chinese Medicine Commodity Trading Center, emphasizing brand value, deep collaboration among five business segments, and the integration of online and offline operations [3] - The center aims to leverage its existing advantages in resource integration, platform operation, and industry chain services to respond to trends in standardization, digitalization, and integration, providing more efficient, transparent, and valuable services to clients in the industry [3]

Core Viewpoint - The traditional Chinese medicine company Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has reported its first loss in ten years, highlighting the challenges faced by the industry during a significant transformation period [2][4]. Financial Performance - Zhenbaodao expects a net profit loss of approximately -1.173 billion to -1.012 billion yuan for the fiscal year 2025, marking a dramatic shift from profit to loss compared to the previous year [2]. - The company's net profit has decreased by 330.94% to 367.68% year-on-year, setting a record for the worst performance in its history [2]. - In the first half of 2025, the company's revenue plummeted by 57.04% to 713 million yuan, with a net loss of 78.29 million yuan, a 119.9% decline year-on-year [6]. Market Challenges - The decline in performance is attributed to several factors, including lower-than-expected sales of core products, price reductions, and significant credit impairment losses of approximately 395 million yuan [4][6]. - The company’s core products, which account for over 70% of its revenue, have been affected by national procurement policies and ongoing healthcare cost controls [4][5]. Strategic Issues - Zhenbaodao's heavy reliance on traditional products and slow innovation has led to strategic difficulties, forcing the company to drastically cut sales and R&D expenses to maintain cash flow [4][6]. - The company’s R&D expenditure has significantly decreased by 52.64% to 37.99 million yuan, representing only 2.60% of its revenue, which is well below the industry average [7]. Governance Concerns - The company faced criticism from the Shanghai Stock Exchange for a 425 million yuan equity transfer that bypassed required approval processes, raising governance concerns [8][9]. - Despite the financial downturn, Zhenbaodao continued to distribute dividends totaling 141 million yuan in 2024, leading to market skepticism regarding the management's priorities and potential wealth transfer to major shareholders [9]. Industry Outlook - The significant loss signals a broader trend where traditional Chinese medicine companies relying on single products and inefficient operations may struggle to survive as procurement practices become more standardized [10]. - Zhenbaodao is attempting to adjust its strategy by focusing on innovation in traditional Chinese medicine, biopharmaceuticals, and chemical drugs, while also restructuring its marketing approach [10].

登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示： ■ 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 证券代码：603567证券简称：珍宝岛公告编号：临2026-009 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动触及1%刻度的提示性公告 黑龙江创达集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 2.信息披露义务人信息 ■ 3.一致行动人信息 上述信息披露义务人无一致行动人。 二、权益变动触及1%刻度的基本情况 黑龙江珍宝岛药业股份有限公司(以下简称"公司")于2026年2月5日收到公司控股股东黑龙江创达集团有 限公司（以下简称"创达集团"）的通知,获悉创达集团发行的2023年面向专业投资者非公开发行可交换 公司债券（第一期）和2023年面向专业投资者非公开发行可交换公司债券（第二期）的债券持有人于 2026年1月13日-2026年2月4日发生换股10,511,854股，导致创达集团持股比例被动下降，持有公司股份 比例从56.98%减少至55.86%，权益变动触及 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临2026-009 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________ | 2.信息披露义务人信息 | 信息披露义 务人名称 | | 投资者身份 | 统一社会信用代码 | 住所 | | --- | --- | --- | --- | --- | | | 控股股东/实控人 ☑ | | | 虎 林 市 解 放 西 | | 黑龙江创达 | | | | | | 集团有限公 | □ 控股股东/实控人 | | ☑9123038156060139X7 | 街 北 检 察 院 东 | | | 的一致行动人 | | | 侧宝润香里 1 号 | | 司 | □ 其他直接持股股 | | □ 不适用 | 楼 1 号门市 | | | 东 | | | | 黑龙江珍宝岛药业股份有限公司 关于控股股东权 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-008 公司控股股东创达集团 2023 年面向专业投资者非公开发行可交换公司债券 （第二期）已发行完毕，目前进入换股期。为了保障"23 创 02EB"债券持有人 利益，创达集团决定将换股价格向下修正。 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第二期）（以下简称"本期可交 债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 6 月 28 日完成本期可交债的发行。本期 可交债简称"23 创 02EB"，债券代码为"137177"，发行规模 0.9 亿元，债券期 限 3 年。具体内容详见公司于 2023 年 ...

Summary of Key Points Core Viewpoint - On February 4, a block trade of 1.36 million shares of Zhenbao Island was executed, amounting to 10.5264 million yuan, which accounted for 8.46% of the total trading volume for the day. The transaction price was 7.74 yuan, representing a discount of 10.31% compared to the market closing price of 8.63 yuan [1]. Group 1 - The block trade involved a total of 1.36 million shares of Zhenbao Island [1]. - The total transaction value for the block trade was 10.5264 million yuan [1]. - The transaction price of 7.74 yuan was 10.31% lower than the market closing price of 8.63 yuan [1]. Group 2 - The block trade occurred on February 4, 2026 [2]. - Multiple brokerage firms participated in the trade, with varying transaction amounts and volumes [2]. - The trading volume for the block trade was 136,000 shares, with specific amounts allocated to different brokerage firms [2].